Sign In
CPSI Share                                                                      
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ ​​
Publication Type: Safety Notice
Single or Multiple Incident: Multiple
Date: 12/7/2021 12:00:00 AM
Country: Australia

This safety notice addresses the use of the monoclonal antibodies, casirivimab and imdevimab, used in the treatment of COVID-19 and post-exposure prophylaxis against COVID-19. The restricted indications are provided in the alert as well as safety risks associated with the packaging of the drugs. Information comparing the initial use of the products versus the updated Australian Register of Therapeutic Goods guidelines is available in the alert.

Additional Details

monoclonal antibodies, casirivimab. imdevimab, sotrovimab, COVID-19 vaccine

Ensuring the safe and appropriate use of casirivimab and imdevimab